Clinical Trials on Chronic Mitral Disease

Total 379319 results

Dong-A ST Co., Ltd.

Recruiting

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Hepatitis B

Korea, Republic of
Universitätsklinikum Hamburg-Eppendorf
Helmholtz Zentrum München; LMU Klinikum; German Center for Infection Research; Medical... and other collaborators

Recruiting

A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Chronic Hepatitis B

Germany
University of Roma La Sapienza

Unknown

Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)

Non Alcoholic Fatty Liver Disease | Chronic Hepatitis C Virus

Italy
Chinese University of Hong Kong

Recruiting

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

Chronic Hepatitis B

Hong Kong
InnovHeart

Active, not recruiting

SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation

Heart Valve Diseases | Mitral Regurgitation | Valve Heart Disease | Mitral Valve Disease | Mitral Disease

Lithuania, Denmark, Hungary
Abbott Medical Devices

Completed

AVJ-514 Japan Trial

Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With Insufficiency

Japan
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

Post Liver Transplant | Recurrent Chronic Hepatitis C Virus

United States, Spain, New Zealand, France, Germany
National Cheng-Kung University Hospital

Recruiting

The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase and Significant Liver Injury.

Chronic Hepatitis b

Taiwan
Shanghai Pudong Hospital

Not yet recruiting

Plasma Purification and Chronic Hepatitis B

Chronic Hepatitis b
Beijing Friendship Hospital
Beijing Ditan Hospital; Nanfang Hospital of Southern Medical University; Ruijin... and other collaborators

Active, not recruiting

Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients

Chronic Hepatitis b

China
Beijing Ditan Hospital

Unknown

A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis

Chronic Hepatitis b

China
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat' (Track&Trace)

Chronic Hepatitis c

Netherlands
AbbVie
IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Chronic Hepatitis C, Genotype 1 or 4
The Catholic University of Korea

Unknown

Treatment Efficacy and Safety of TDF-TAF Switch Study in South Korea

Chronic Hepatitis b

Korea, Republic of
Zhongshan Hospital Xiamen University

Unknown

Study on Effect of Intestinal Microbiota Transplantation in Chronic Hepatitis B (CHB)

Chronic Hepatitis b

China
Qin Ning

Unknown

Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients (NPGV)

Chronic Hepatitis b
Yao Xie

Unknown

The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
St Vincent's Hospital Melbourne
National Health and Medical Research Council, Australia

Unknown

Determinants of Virological Response After Discontinuation of Nucleoside Analogue Therapy in Hepatitis B Patients (STOP)

Chronic Hepatitis B.

Australia
Novartis Pharmaceuticals

Withdrawn

Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks

Compensated Chronic Hepatitis B

United States, Puerto Rico
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b

Chronic Hepatitis b

China
Hanmi Pharmaceutical Company Limited

Unknown

Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

Chronic Hepatitis C Virus Genotype I

Mexico
Novartis Pharmaceuticals

Completed

Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B

Compensated Chronic Hepatitis B

China
Bristol-Myers Squibb

Withdrawn

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Chronic Hepatitis C Virus Genotype 1

United States
Southeast University, China

Unknown

Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission

Chronic Hepatitis B, Gestation
Great Ormond Street Hospital for Children NHS Foundation...
Cukurova University; University of Kiel; Athens General Children's Hospital "Pan...

Active, not recruiting

Calcium Balance Studies in Children With CKD and on Dialysis (Cal-Bal)

Chronic Kidney Disease Mineral and Bone Disorder

United Kingdom
Maimónides Biomedical Research Institute of Córdoba

Completed

Artificial Intelligence: a New Alternative to Analyse CKD-MBD in Hemodialysis

Chronic Kidney Disease Mineral and Bone Disorder

Spain
Hanyang University
Roche Pharma AG

Completed

Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients (Addwin)

Chronic Hepatitis C

Korea, Republic of
Bristol-Myers Squibb

Terminated

Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Chronic Hepatitis C

China
Novartis

Completed

Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients

Chronic Hepatitis C

Japan
OPKO Health, Inc.

Completed

Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin

Hepatitis, Viral, Human | Chronic Hepatitis C

Canada
Alios Biopharma Inc.

Completed

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

France, Moldova, Republic of, Georgia
AbbVie

Completed

The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France (OPALE)

Chronic Hepatitis C

France
AbbVie

Completed

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland (REACH)

Chronic Hepatitis C
AbbVie
Cato Research; IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada (AMBER)

Chronic Hepatitis C
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

Chronic Hepatitis C
AbbVie
IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania

Chronic Hepatitis C
Bristol-Myers Squibb

Completed

Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Debiopharm International SA

Terminated

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Hepatitis C

United States
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
Hoffmann-La Roche

Completed

Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)

Chronic Hepatitis C

Germany
Pharco Pharmaceuticals

Unknown

A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

Chronic Hepatitis C

Egypt
Center For Hepatitis C, Atlanta, GA

Completed

The SIM-SOF Trial for Hepatitis C

Chronic Hepatitis C

United States
Bristol-Myers Squibb

No longer available

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Chronic Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Chronic Hepatitis C
Beijing 302 Hospital

Unknown

Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection

Chronic Hepatitis C

China
Haukeland University Hospital
Hoffmann-La Roche; Bergen Prison, Norwegian Correctional Service

Terminated

Hepatitis C Treatment of Inmates (PEGPRI)

Chronic Hepatitis C

Norway
Beijing Kawin Technology Share-Holding Co., Ltd.

Completed

A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C

Chronic Hepatitis C

China
CureTech Ltd
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection

Chronic Hepatitis C

Israel
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands

3

Subscribe